Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes
Authors
Keywords
Endocrinology, Exenatide once weekly, GLP-1 receptor agonists, Incretin therapy, Type 2 diabetes mellitus
Journal
ADVANCES IN THERAPY
Volume 31, Issue 3, Pages 247-263
Publisher
Springer Nature
Online
2014-02-17
DOI
10.1007/s12325-014-0101-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of Exenatide on Kidney Function, Adverse Events, and Clinical End Points of Kidney Disease in Type 2 Diabetes
- (2013) Katherine R. Tuttle et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
- (2013) John B. Buse et al. ANNALS OF INTERNAL MEDICINE
- Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
- (2013) R. A. DeFronzo et al. DIABETES CARE
- A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks
- (2013) M. A. Nauck DIABETES CARE
- Interpreting Adverse Signals in Diabetes Drug Development Programs
- (2013) C. J. Bailey DIABETES CARE
- Do GLP-1-Based Therapies Increase Cancer Risk?
- (2013) M. A. Nauck et al. DIABETES CARE
- Role of Reduced -Cell Mass Versus Impaired -Cell Function in the Pathogenesis of Type 2 Diabetes
- (2013) J. J. Meier et al. DIABETES CARE
- A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 therapies safe?
- (2013) P. C. Butler et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2014
- (2013) DIABETES CARE
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m2in Spain
- (2013) Tiago Fonseca et al. JOURNAL OF MEDICAL ECONOMICS
- Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTcinterval in healthy subjects
- (2012) Börje Darpö et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy
- (2012) G. S. Tobin et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
- (2012) R. Pencek et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US
- (2012) Yevgeniy Samyshkin et al. JOURNAL OF MEDICAL ECONOMICS
- Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States
- (2012) Anne-Laure Guillermin et al. JOURNAL OF MEDICAL ECONOMICS
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
- (2011) D. Russell-Jones et al. DIABETES CARE
- Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
- (2011) Mary Beth DeYoung et al. Diabetes Technology & Therapeutics
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland
- (2011) M. Brändle et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects
- (2011) E. Cersosimo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes
- (2011) Padma Sathyanarayana et al. Obesity
- Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK
- (2011) Amélie Beaudet et al. JOURNAL OF MEDICAL ECONOMICS
- Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing
- (2010) Mark Fineman et al. CLINICAL PHARMACOKINETICS
- Patient perspectives on once-weekly medications for diabetes
- (2010) W. H. Polonsky et al. DIABETES OBESITY & METABOLISM
- Review Paper: Absorbable Polymeric Surgical Sutures: Chemistry, Production, Properties, Biodegradability, and Performance
- (2010) Chennakkattu Krishna Sadasivan Pillai et al. JOURNAL OF BIOMATERIALS APPLICATIONS
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
- (2009) David D. Dore et al. CURRENT MEDICAL RESEARCH AND OPINION
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study
- (2009) R. A. Noel et al. DIABETES CARE
- Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use
- (2009) David M. Kendall et al. European Journal of Internal Medicine
- Incretin-based therapies for type 2 diabetes mellitus
- (2009) Julie A. Lovshin et al. Nature Reviews Endocrinology
- Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
- (2008) Antonio Cervera et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats
- (2008) P. J. Larsen et al. DIABETES OBESITY & METABOLISM
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search